These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 23825071

  • 1. Erythropoietin ameliorates podocyte injury in advanced diabetic nephropathy in the db/db mouse.
    Loeffler I, Rüster C, Franke S, Liebisch M, Wolf G.
    Am J Physiol Renal Physiol; 2013 Sep 15; 305(6):F911-8. PubMed ID: 23825071
    [Abstract] [Full Text] [Related]

  • 2. Erythropoietin protects podocytes from damage by advanced glycation end-products.
    Ruester C, Franke S, Bondeva T, Wolf G.
    Nephron Exp Nephrol; 2011 Sep 15; 117(1):e21-30. PubMed ID: 20689331
    [Abstract] [Full Text] [Related]

  • 3. Erythropoietin prevents diabetes-induced podocyte damage.
    Schiffer M, Park JK, Tossidou I, Bartels J, Shushakova N, Menne J, Fliser D.
    Kidney Blood Press Res; 2008 Sep 15; 31(6):411-5. PubMed ID: 19096223
    [Abstract] [Full Text] [Related]

  • 4. The continuous erythropoietin receptor activator affects different pathways of diabetic renal injury.
    Menne J, Park JK, Shushakova N, Mengel M, Meier M, Fliser D.
    J Am Soc Nephrol; 2007 Jul 15; 18(7):2046-53. PubMed ID: 17554150
    [Abstract] [Full Text] [Related]

  • 5. Advanced glycation end-products induce cell cycle arrest and hypertrophy in podocytes.
    Rüster C, Bondeva T, Franke S, Förster M, Wolf G.
    Nephrol Dial Transplant; 2008 Jul 15; 23(7):2179-91. PubMed ID: 18344241
    [Abstract] [Full Text] [Related]

  • 6. Advanced glycation end products inhibit adhesion ability of differentiated podocytes in a neuropilin-1-dependent manner.
    Bondeva T, Wojciech S, Wolf G.
    Am J Physiol Renal Physiol; 2011 Oct 15; 301(4):F852-70. PubMed ID: 21734098
    [Abstract] [Full Text] [Related]

  • 7. Parathyroid hormone-related protein induces hypertrophy in podocytes via TGF-beta(1) and p27(Kip1): implications for diabetic nephropathy.
    Romero M, Ortega A, Izquierdo A, López-Luna P, Bosch RJ.
    Nephrol Dial Transplant; 2010 Aug 15; 25(8):2447-57. PubMed ID: 20200004
    [Abstract] [Full Text] [Related]

  • 8. p27(Kip1) Knockout mice are protected from diabetic nephropathy: evidence for p27(Kip1) haplotype insufficiency.
    Wolf G, Schanze A, Stahl RA, Shankland SJ, Amann K.
    Kidney Int; 2005 Oct 15; 68(4):1583-9. PubMed ID: 16164635
    [Abstract] [Full Text] [Related]

  • 9. Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy.
    Jung E, Kim J, Ho Kim S, Kim S, Cho MH.
    Eur J Pharmacol; 2015 Aug 15; 761():116-24. PubMed ID: 25977232
    [Abstract] [Full Text] [Related]

  • 10. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy.
    Susztak K, Raff AC, Schiffer M, Böttinger EP.
    Diabetes; 2006 Jan 15; 55(1):225-33. PubMed ID: 16380497
    [Abstract] [Full Text] [Related]

  • 11. Galectin-9 inhibits glomerular hypertrophy in db/db diabetic mice via cell-cycle-dependent mechanisms.
    Baba M, Wada J, Eguchi J, Hashimoto I, Okada T, Yasuhara A, Shikata K, Kanwar YS, Makino H.
    J Am Soc Nephrol; 2005 Nov 15; 16(11):3222-34. PubMed ID: 16177004
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms.
    Okada T, Wada J, Hida K, Eguchi J, Hashimoto I, Baba M, Yasuhara A, Shikata K, Makino H.
    Diabetes; 2006 Jun 15; 55(6):1666-77. PubMed ID: 16731829
    [Abstract] [Full Text] [Related]

  • 14. Schisandra chinensis fruit extract attenuates albuminuria and protects podocyte integrity in a mouse model of streptozotocin-induced diabetic nephropathy.
    Zhang M, Liu M, Xiong M, Gong J, Tan X.
    J Ethnopharmacol; 2012 May 07; 141(1):111-8. PubMed ID: 22353431
    [Abstract] [Full Text] [Related]

  • 15. Chronic erythropoietin treatment affects different molecular pathways of diabetic cardiomyopathy in mouse.
    Shushakova N, Park JK, Menne J, Fliser D.
    Eur J Clin Invest; 2009 Sep 07; 39(9):755-60. PubMed ID: 19614950
    [Abstract] [Full Text] [Related]

  • 16. NFAT2 inhibitor ameliorates diabetic nephropathy and podocyte injury in db/db mice.
    Zhang L, Li R, Shi W, Liang X, Liu S, Ye Z, Yu C, Chen Y, Zhang B, Wang W, Lai Y, Ma J, Li Z, Tan X.
    Br J Pharmacol; 2013 Sep 07; 170(2):426-39. PubMed ID: 23826864
    [Abstract] [Full Text] [Related]

  • 17. Renoprotection by continuous erythropoietin receptor activator in puromycin aminonucleoside-induced nephrotic syndrome.
    Aizawa K, Takeda S, Tashiro Y, Yorozu K, Hirata M, Kanada H, Moriguchi Y, Endo K.
    Am J Nephrol; 2012 Sep 07; 36(5):419-26. PubMed ID: 23128049
    [Abstract] [Full Text] [Related]

  • 18. Activation of the receptor for advanced glycation end products induces nuclear inhibitor of protein phosphatase-1 suppression.
    Liebisch M, Bondeva T, Franke S, Daniel C, Amann K, Wolf G.
    Kidney Int; 2014 Jul 07; 86(1):103-17. PubMed ID: 24476693
    [Abstract] [Full Text] [Related]

  • 19. Mesenchymal stem cells ameliorate podocyte injury and proteinuria in a type 1 diabetic nephropathy rat model.
    Wang S, Li Y, Zhao J, Zhang J, Huang Y.
    Biol Blood Marrow Transplant; 2013 Apr 07; 19(4):538-46. PubMed ID: 23295166
    [Abstract] [Full Text] [Related]

  • 20. Advanced glycation end products suppress neuropilin-1 expression in podocytes by a reduction in Sp1-dependent transcriptional activity.
    Bondeva T, Wolf G.
    Am J Nephrol; 2009 Apr 07; 30(4):336-45. PubMed ID: 19590177
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.